Astrana Health, Inc. (NASDAQ:ASTH) Short Interest Down 17.9% in November

Astrana Health, Inc. (NASDAQ:ASTH) was the target of a large decline in short interest during the month of November. As of November 15th, there was short interest totalling 1,560,000 shares, a decline of 17.9% from the October 31st total of 1,900,000 shares. Currently, 4.4% of the shares of the company are short sold. Based on an average daily trading volume, of 286,600 shares, the days-to-cover ratio is currently 5.4 days.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Central Pacific Bank Trust Division purchased a new stake in Astrana Health in the 3rd quarter worth approximately $160,000. SG Americas Securities LLC purchased a new position in Astrana Health during the third quarter valued at approximately $680,000. Granite Bay Wealth Management LLC bought a new position in shares of Astrana Health in the third quarter worth approximately $290,000. Handelsbanken Fonder AB purchased a new stake in shares of Astrana Health in the third quarter worth $492,000. Finally, GAMMA Investing LLC purchased a new stake in shares of Astrana Health in the third quarter worth $34,000. 52.77% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ASTH. Robert W. Baird raised their price target on shares of Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. BTIG Research raised their target price on shares of Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a report on Thursday, October 3rd. KeyCorp began coverage on shares of Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen initiated coverage on Astrana Health in a report on Monday, October 14th. They set a “buy” rating and a $66.00 price target on the stock. Finally, Truist Financial raised their price target on Astrana Health from $50.00 to $59.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $65.17.

Astrana Health Stock Up 0.9 %

ASTH opened at $43.25 on Friday. The firm’s 50 day simple moving average is $52.79 and its two-hundred day simple moving average is $48.00. The company has a market capitalization of $2.43 billion, a PE ratio of 33.27, a PEG ratio of 1.99 and a beta of 1.24. Astrana Health has a 1-year low of $32.32 and a 1-year high of $63.20. The company has a current ratio of 1.91, a quick ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last announced its earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting analysts’ consensus estimates of $0.33. Astrana Health had a return on equity of 9.37% and a net margin of 3.63%. The company had revenue of $478.71 million for the quarter, compared to analysts’ expectations of $462.01 million. During the same period last year, the firm earned $0.47 EPS. As a group, equities analysts forecast that Astrana Health will post 1.17 EPS for the current year.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.